<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538755</url>
  </required_header>
  <id_info>
    <org_study_id>2020p002760-1</org_study_id>
    <nct_id>NCT04538755</nct_id>
  </id_info>
  <brief_title>DAW2020 on OSA Endotypic Traits</brief_title>
  <acronym>SedOSA</acronym>
  <official_title>Effect of DAW2020 on Endotypic Traits in OSA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and has major health implications but treatment&#xD;
      options are limited. Some OSA patients with low arousal threshold wake up prematurely during&#xD;
      an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle&#xD;
      recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this&#xD;
      protocol the investigators will test the effect of DAW2020 administered before sleep on OSA&#xD;
      phenotype traits and OSA severity during sleep.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two overnight sleep studies will be performed: a drug night and a placebo night. The patient&#xD;
      will breath spontaneously (without CPAP) for both nights. On the study nights, subjects will&#xD;
      present to the laboratory in the evening and be instrumented with a full polysomnigraphy for&#xD;
      monitoring sleep, physiological variables (endotypes), and respiratory events. A history and&#xD;
      physical examination will be performed on each night prior to beginning the study, as will a&#xD;
      urine pregnancy test in premenopausal women. DAW2020 34 mg will be given 4 hours before&#xD;
      lights out. Subjects will sleep at least 50% of the night in the supine position. At least&#xD;
      four hours of sleep with high quality signal acquisition will be required for a study to be&#xD;
      judged adequate. After the first overnight study is completed, there will be a one-week&#xD;
      washout period prior to crossing over to the other treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of DAW2020 on arousal threshold (%eupnea)</measure>
    <time_frame>1 night</time_frame>
    <description>Arousal threshold will be calculated using diaphragm EMG</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Obstructive Sleep Apnea (OSA)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule 4 hours before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAW2020</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DAW2020 capsule 4 hours before sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo before sleep</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAW2020 oral capsule</intervention_name>
    <description>DAW2020 34 mg 4 h before sleep, single night administration</description>
    <arm_group_label>DAW2020</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate-to-severe OSA (AHI â‰¥ 15 events/hr)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All participants will be healthy and without major organ system disease that would&#xD;
             preclude undergoing the physiological measurements.&#xD;
&#xD;
          -  Use of medications expected to stimulate or depress respiration (including opioids,&#xD;
             barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic&#xD;
             acid).&#xD;
&#xD;
          -  Use of SNRIs/SSRIs.&#xD;
&#xD;
          -  Conditions likely to affect OSA physiology: neuromuscular disease or other major&#xD;
             neurological disorder, heart failure (also below), or any other unstable major medical&#xD;
             condition.&#xD;
&#xD;
          -  Sleep disordered breathing or respiratory disorders other than obstructive sleep&#xD;
             apnea:&#xD;
&#xD;
          -  Other sleep disorders: periodic limb movements (periodic limb movement arousal index &gt;&#xD;
             10/hr), narcolepsy, or parasomnias.&#xD;
&#xD;
          -  Hypersensitivity to the study drug (angioedema or urticaria)&#xD;
&#xD;
          -  Contraindications to DAW2020&#xD;
&#xD;
          -  Use of medications that lengthen QTc interval&#xD;
&#xD;
          -  Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease&#xD;
&#xD;
          -  Severe claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David A Wellman, MD</last_name>
    <phone>617-732-6541</phone>
    <email>awellman@rics.bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren B Hess, BS</last_name>
      <phone>617-732-8976</phone>
      <email>lhess1@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Andrew Wellman</investigator_full_name>
    <investigator_title>Associate professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

